Given the projected growth in the exoskeleton market and Ekso Bionics' recent partnerships and initiatives, I anticipate that EKSO is positioned for significant upward momentum. The optimism surrounding its business prospects, particularly following the favorable Medicare reimbursement announcement, reinforces my decision to buy this stock.